|
|
|
Bicycle Therapeutics and Cancer Research UK to develop New Bicycle® Immuno-oncology Candidate, BT7401
“The modular nature of the Bicycle platform enables a number of opportunities to generate new therapeutics that could address unmet need in oncology and other serious diseases,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle. “This new collaboration marks yet another initiative designed to help us bring a potentially important Bicycle-based therapy to patients more efficiently. We are excited to extend our relationship with Cancer Research UK by collaborating with them on BT7401. Cancer Research UK is a partner of choice, with a broad network of collaborators and extensive expertise in cancer treatment. Through our collaboration, we believe we will be able to characterize the biologic and therapeutic profile of BT7401, which we’re pleased to add to our growing portfolio of novel immuno-oncology assets.”
|
|
Nektar and BMS expand the active clinical development program for bempeg + nivolumab in adjuvant melanoma and MIBC
“Bristol-Myers Squibb and Nektar view bempeg as an important asset and IL-2 as an important target,” said Fouad Namouni, M.D., head of oncology development, Bristol-Myers Squibb. “We look forward to expanding the registrational program currently underway for bempeg and are committed to the development of potential new combination therapies to address the unmet needs of patients living with cancer.”
|
|
|
Lilly Announces Agreement to Acquire Dermira
Lilly announced its agreement to acquire Dermira, a biopharmaceutical company that is focussed on finding treatment for chronic skin conditions. The all-cash transaction of 1.1 Billion dollars will see Lilly Buying Dermira for 18.75 dollars/share. It will allow Lilly to expand its immunology pipeline by adding Dermira's lebrikizumab, a novel, investigational, monoclonal antibody that is engineered to bind IL-13. The drug is being evaluated in Phase 3 clinical trial for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older
|
|
Biogen Acquires Alzheimer's and Parkinson's Asset from Pfizer
Biogen announced that it would acquire PF-05251749, a clinical-stage circadian rhythm regulator that can have implications for Alzheimers and Parkinson's patients. PF-05251749 is a novel casein kinase inhibitor that penetrates the blood-brain barrier. Biogen will pay 75 million dollars up front, with 635 million dollars in milestone payments for the asset.
|
|
Borisy's new company, EQRx takes aim at drug prices
Venture capitalist Alexis Borisy and his team launched a new company called EQRx with 200 M dollars series A, aiming to reduce the drug pricing. He said they have the plan to bring ten drugs in the next ten years to the market. As we enter the election, drug pricing remains the top trending News, and it looks like it's not going to be replaced very soon.
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|